Details

Autor(en) / Beteiligte

• Shields, Adrian M
• Anantharachagan, Ariharan
• Arumugakani, Gururaj
• Baker, Kenneth
• Bahal, Sameer
• Baxendale, Helen
• Bermingham, William
• Bhole, Malini
• Boules, Evon
• Bright, Philip
• Chopra, Charu
• Cliffe, Lucy
• Cleave, Betsy
• Dempster, John
• Devlin, Lisa
• Dhalla, Fatima
• Diwakar, Lavanya
• Drewe, Elizabeth
• Duncan, Christopher
• Dziadzio, Magdalena
• Elcombe, Suzanne
• Elkhalifa, Shuayb
• Gennery, Andrew
• Ghanta, Harichandrana
• Goddard, Sarah
• Grigoriadou, Sofia
• Hackett, Scott
• Hayman, Grant
• Herriot, Richard
• Herwadkar, Archana
• Huissoon, Aarnoud
• Jain, Rashmi
• Jolles, Stephen
• Johnston, Sarah
• Khan, Sujoy
• Laffan, James
• Lane, Peter
• Leeman, Lucy
• Lowe, David M
• Mahabir, Shanti
• Lochlainn, Dylan James Mac
• McDermott, Elizabeth
• Misbah, Siraj
• Moghaddas, Fiona
• Morsi, Hadeil
• Murng, Sai
• Noorani, Sadia
• O'Brien, Rachael
• Patel, Smita
• Price, Arthur
• Rahman, Tasneem
• Seneviratne, Suranjith
• Shrimpton, Anna
• Stroud, Catherine
• Thomas, Moira
• Townsend, Katie
• Vaitla, Prashantha
• Verma, Nisha
• Williams, Anthony
• Burns, Siobhan O
• Savic, Sinisa
• Richter, Alex G

Titel

Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

Ist Teil von

• Clinical and experimental immunology, 2022-09, Vol.209 (3), p.247-258

Ort / Verlag

England

Erscheinungsjahr

2022

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort.